{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:15:38Z","timestamp":1782440138951,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002726","name":"Beijing Normal University","doi-asserted-by":"publisher","award":["BNU110107977"],"award-info":[{"award-number":["BNU110107977"]}],"id":[{"id":"10.13039\/501100002726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant melanoma, an increasingly common form of skin cancer, is a major threat to public health, especially when the disease progresses past skin lesions to the stage of advanced metastasis. Targeted drug development is an effective strategy for the treatment of malignant melanoma. In this work, a new antimelanoma tumor peptide, the lebestatin\u2013annexin V (designated LbtA5) fusion protein, was developed and synthesized by recombinant DNA techniques. As a control, annexin V (designated ANV) was also synthesized by the same method. The fusion protein combines annexin V, which specifically recognizes and binds phosphatidylserine, with the disintegrin lebestatin (lbt), a polypeptide that specifically recognizes and binds integrin \u03b11\u03b21. LbtA5 was successfully prepared with good stability and high purity while retaining the dual biological activity of ANV and lbt. MTT assays demonstrated that both ANV and LbtA5 could reduce the viability of melanoma B16F10 cells, but the activity of the fusion protein LbtA5 was superior to that of ANV. The tumor volume growth was slowed in a mouse xenograft model treated with ANV and LbtA5, and the inhibitory effect of high concentrations of LbtA5 was significantly better than that of the same dose of ANV and was comparable to that of DTIC, a drug used clinically for melanoma treatment. The hematoxylin and eosin (H&amp;E) staining test showed that ANV and LbtA5 had antitumor effects, but LbtA5 showed a stronger ability to induce melanoma necrosis in mice. Immunohistochemical experiments further showed that ANV and LbtA5 may inhibit tumor growth by inhibiting angiogenesis in tumor tissue. Fluorescence labeling experiments showed that the fusion of ANV with lbt enhanced the targeting of LbtA5 to mouse melanoma tumor tissue, and the amount of target protein in tumor tissue was significantly increased. In conclusion, effective coupling of the integrin \u03b11\u03b21-specific recognition molecule lbt confers stronger biological antimelanoma effects of ANV, which may be achieved by the dual effects of effective inhibition of B16F10 melanoma cell viability and inhibition of tumor tissue angiogenesis. The present study describes a new potential strategy for the application of the promising recombinant fusion protein LbtA5 in the treatment of various cancers, including malignant melanoma.<\/jats:p>","DOI":"10.3390\/ijms24043859","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:09:21Z","timestamp":1676430561000},"page":"3859","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice"],"prefix":"10.3390","volume":"24","author":[{"given":"Jingyi","family":"Zhu","sequence":"first","affiliation":[{"name":"Beijing Key Lab of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Li","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Beijing Normal University, Beijing 100875, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenling","family":"Gao","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Beijing Normal University, Beijing 100875, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8442-864X","authenticated-orcid":false,"given":"Jian","family":"Jing","sequence":"additional","affiliation":[{"name":"Beijing Key Lab of Biotechnology and Genetic Engineering, College of Life Sciences, Beijing Normal University, Beijing 100875, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"215857","DOI":"10.1016\/j.canlet.2022.215857","article-title":"Annexin A5 as a targeting agent for cancer treatment","volume":"547","author":"Woodward","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"42602","DOI":"10.18632\/oncotarget.16645","article-title":"Anti-cancer activity of Annexin V in murine melanoma model by suppressing tumor angiogenesis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cac2.12364","article-title":"Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma","volume":"42","author":"Li","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semcancer.2019.06.015","article-title":"Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components","volume":"59","author":"Cho","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kuo, Y.J., Chung, C.H., and Huang, T.F. (2019). From Discovery of Snake Venom Disintegrins to A Safer Therapeutic Antithrombotic Agent. Toxins, 11.","DOI":"10.3390\/toxins11070372"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13612","DOI":"10.1073\/pnas.94.25.13612","article-title":"Angiogenesis promoted by vascular endothelial growth factor: Regulation through alpha1beta1 and alpha2beta1 integrins","volume":"94","author":"Senger","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114149","DOI":"10.1016\/j.bcp.2020.114149","article-title":"Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review","volume":"181","author":"Schonthal","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/labinvest.3700350","article-title":"Lebestatin, a disintegrin from Macrovipera venom, inhibits integrin-mediated cell adhesion, migration and angiogenesis","volume":"85","author":"Olfa","year":"2005","journal-title":"Lab. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/pcmr.12880","article-title":"Emerging strategies to treat rare and intractable subtypes of melanoma","volume":"34","author":"Alicea","year":"2020","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12096","DOI":"10.1021\/acsnano.8b05292","article-title":"Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth","volume":"12","author":"Deng","year":"2018","journal-title":"ACS Nano"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.4155\/fmc.12.98","article-title":"Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: A comparative study","volume":"4","author":"Almansour","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2021.10.028","article-title":"RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy","volume":"340","author":"Sheikh","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0002-9440(10)64363-5","article-title":"The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis","volume":"160","author":"Senger","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/bcr3454","article-title":"beta1-Integrin via NF-kappaB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer","volume":"15","author":"Nam","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chen, X., Wang, Y., Liu, H., Zhang, J., Wang, J., Jin, X., and Ma, Y. (2022). CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinbeta1. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10318-8"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.matbio.2022.08.002","article-title":"Chemotherapy treatment induces pro-invasive changes in liver ECM composition","volume":"112","author":"Guarin","year":"2022","journal-title":"Matrix Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20544","DOI":"10.1038\/s41598-022-25138-w","article-title":"The human ion channel TRPM2 modulates migration and invasion in neuroblastoma through regulation of integrin expression","volume":"12","author":"Bao","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/S0049-3848(10)70031-1","article-title":"Targeting anionic phospholipids on tumor blood vessels and tumor cells","volume":"125","author":"Thorpe","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1536012117708722","DOI":"10.1177\/1536012117708722","article-title":"Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e149473","DOI":"10.1172\/JCI149473","article-title":"ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine","volume":"132","author":"Xu","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1111\/ijd.13689","article-title":"Elevated levels of serum IgM anti-phosphatidylserine-prothrombin complex antibodies in patients with cancer-associated vasculitis","volume":"56","author":"Kawakami","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2014.03.043","article-title":"Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice","volume":"183","author":"Zhang","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.tranon.2018.06.008","article-title":"PSP1, a Phosphatidylserine-Recognizing Peptide, Is Useful for Visualizing Radiation-Induced Apoptosis in Colorectal Cancer In Vitro and In Vivo","volume":"11","author":"Bae","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108620","DOI":"10.1016\/j.celrep.2020.108620","article-title":"Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma","volume":"34","author":"Budhu","year":"2021","journal-title":"Cell Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41467-020-14821-z","article-title":"Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment","volume":"11","author":"Kang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1535-7163.MCT-16-0263","article-title":"Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide","volume":"16","author":"Krais","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2018.03.027","article-title":"Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer","volume":"425","author":"Virani","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/srep03565","article-title":"Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy","volume":"3","author":"Qiu","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4161\/cbt.21354","article-title":"Regulation of the human TRAIL gene","volume":"13","author":"Allen","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"755995","DOI":"10.3389\/fimmu.2021.755995","article-title":"Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells","volume":"12","author":"MacDonald","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2009.03.041","article-title":"Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner","volume":"283","author":"Lima","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.2174\/138161207782023793","article-title":"Anti-angiogenesis and RGD-containing snake venom disintegrins","volume":"13","author":"Swenson","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and Metabolism in the Tumor Microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metabolism."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ijc.22688","article-title":"Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model","volume":"121","author":"Jia","year":"2007","journal-title":"Int. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3859\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:53Z","timestamp":1760121353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043859"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043859","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}